Chronic Kidney Disease

Compared to nonusers, patients with type 2 diabetes and acute kidney disease administered SGLT-2is had a significantly lower risk of mortality, major adverse kidney events, and major adverse cardiovascular events.

A new study is raising awareness around the effects of structural racism on the prevalence of chronic health conditions.

Thyroid dysfunction was greater among patients with more severe CKD coupled with a high urine protein level.

These results highlight the potential of preventing increasing CKD burden and of preventing subsequent cardiovascular conditions, especially given current rates of obesity among adolescents.

Patients who reported almost daily fresh vegetable consumption had higher eGFR compared to those with occasional consumption and those who consumed salt-preserved vegetables.

These data helped to verify the MDRD-4 and CKD-EPI equations’ accuracy in the estimation of GFR among the Brazilian population.

A new study demonstrated hemoglobin levels significantly increased with ziltivekimab, showing the monoclonal antibody has the potential to serve as a new treatment method for anemia.

Data from a 24-week, prospective trial conducted at a hospital in China provide insight into the effects of roxadustat on iron metabolism relative to use of ESAs in patients using peritoneal dialysis.

At ASN Kidney Week 2023, we collected perspectives from 10 key opinion leaders in nephrology on what they see as the most significant news in their specialty from the past year.

Dhiren Patel, PharmD, and Bob Busch, MD, interview Fatima Cody Stanford, MD, MPH, MPA, an obesity medicine specialist, to examine the cardiovascular (CV) impact of obesity and delve into the potential benefits of newer weight loss medications in mitigating CV risk and heart failure.

Patrick Rossignol, MD, PhD, provides additional perspective on the results of the ALCHEMIST trial from Kidney Week 2023.

Analysis of nearly 15k patients with non-dialysis-dependent CKD and anemia provides insight into contemporary trends in management.

Preliminary data from the open-label RUBY-3 trial were presented at the American Society of Nephrology Kidney Week 2023.

Results of the ZENITH-CKD trial provide evidence of the safety and efficacy profile of combination zibotentan plus dapagliflozin in patients with chronic kidney disease.

Although the DUPLEX trial missed its primary endpoint of eGFR slope in patients with FSGS, results point to greater reductions in proteinuria and in risk of kidney failure with sparsentan use relative to irbesartan—making its case for becoming a standard of care for the glomerular disease.

An analysis of Target-HTN provides new insight into the effects of lorundrostat among patients with uncontrolled or treatment-resistant hypertension.

Rajiv Agarwal, MD, MS, provides insight into an analysis from ASN Kidney Week 2023 detailing the effect of early albuminuria reduction on risk of adverse kidney and cardiovascular outcomes in people with T2D and chronic kidney disease.

John W. Ostrominski, MD, describes the prevalence and overlap of cardiac, renal, and metabolic conditions in US adults over a 20-year period.

Experts discuss the intricate relationship between diabetes, kidney disease, and cardiovascular function and explore the evolving landscape of therapies with cardiorenal benefits.

The FDA has accepted Akebia Therapeutics' resubmission of the vadadustat NDA for anemia in chronic kidney disease. PDUFA date is March 27, 2024.

On October 17, 2023, Ardelyx Inc announced the FDA approval of tenapanor (Xphozah) for reducing serum phosphorus in adults with chronic kidney disease on dialysis as add-on therapy.

On October 10, 2023, Novo Nordisk announced they would be stopping the FLOW trial, which examined the effects of semaglutide 1.0 mg on kidney outcomes in type 2 diabetes, due to early efficacy based on an interim analysis of the trial.

This installment in our Unprevented series examines the growing impact of chronic kidney disease on public health and what those in the field are doing to mitigate this growing crisis.

Eli Lilly and Company and Boehringer Ingelheim announced the FDA approval of empagliflozin (Jardiance) for chronic kidney disease management on September 22, 2023.

Citing more than half a dozen major trials in the 2 years since the release of their 2021 heart failure guidelines, the European Society of Cardiology has released a focused update to their heart failure guidance.